Franklin Biotechnology Discovery Adv (FTDZX)
110.79
+0.84
(+0.76%)
USD |
Mar 20 2023
Key Stats
| Expense Ratio | Total Assets Under Management | Dividend Yield | Turnover Ratio |
|---|---|---|---|
| 0.79% | 798.15M | 0.38% | 26.25% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized All Time Total Returns (Daily) | Max Drawdown (All) |
| -110.80M | -4.15% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. It is non-diversified. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | FBDIX |
| Equity Style | Mid Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Franklin Templeton Investments |
| Prospectus Benchmark Index | |
| NASDAQ Biotechnology PR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Evan McCulloch | 25.47 yrs |
| Wendy Lam | 4.50 yrs |
| Akiva Felt | 3.09 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
77
-110.80M
-2.719B
Category Low
6.230B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of February 28, 2023
Risk
Performance Versus Category
As of March 17, 2023. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of March 17, 2023.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Amgen Inc | 6.73% | 234.72 | 2.15% |
| Vertex Pharmaceuticals Inc | 6.63% | 298.95 | 1.08% |
| Regeneron Pharmaceuticals Inc | 6.09% | 759.25 | 1.55% |
| Gilead Sciences Inc | 5.93% | 79.46 | 2.78% |
| Franklin IFT Money Market | 5.34% | 1.00 | 0.00% |
| Jazz Pharmaceuticals PLC | 4.92% | 137.98 | 2.10% |
| Biogen Inc | 4.48% | 267.91 | 1.80% |
| AstraZeneca PLC ADR | 4.41% | 66.74 | 1.72% |
| Ascendis Pharma A/S ADR | 4.10% | 109.80 | 1.54% |
| PTC Therapeutics Inc | 3.52% | 48.49 | 2.52% |
Basic Info
| Investment Strategy | |
| The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. It is non-diversified. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | FBDIX |
| Equity Style | Mid Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Franklin Templeton Investments |
| Prospectus Benchmark Index | |
| NASDAQ Biotechnology PR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Evan McCulloch | 25.47 yrs |
| Wendy Lam | 4.50 yrs |
| Akiva Felt | 3.09 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (3-17-23) | 0.38% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | -- |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of January 31, 2023
Fund Details
| Key Dates | |
| Inception Date | 9/1/2009 |
| Last Annual Report Date | 4/30/2022 |
| Last Prospectus Date | 9/1/2022 |
| Share Classes | |
| FBDIX | A |
| FBTDX | C |
| FRBRX | Retirement |
| Attributes | |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |